News Headlines

  1. SCHOTT Pharma Invests In Sterile Cartridge Production In Hungary 6/4/2025

    SCHOTT Pharma, a pioneer in drug containment and delivery solutions, is investing more than 100 million euros in its existing site in Lukácsháza, Hungary, to expand its capacity for sterile ready-to-use (RTU) cartridges.

  2. CARBOGEN AMCIS Accelerates Manufacturing Capacity With CHF 25.5 Million Co-Investment At Swiss Sites 6/4/2025

    CARBOGEN AMCIS, a Switzerland-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, is pleased to announce a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland.

  3. Lipella Pharmaceuticals Re-Signs Manufacturing Collaboration Agreement With Cook MyoSite To Support LP-310 Clinical Development 6/4/2025

    Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it has re-signed its manufacturing collaboration agreement with Cook MyoSite, Inc. (“Cook MyoSite”) to support Chemistry, Manufacturing and Control (CMC) documentation supporting our clinical products LP-10 and LP-310.

  4. Zydus To Enter Global Biologics CDMO Business: Plans To Acquire Agenus' U.S. Manufacturing Facilities To Accelerate Development Of Innovative Therapies 6/3/2025

    Zydus Lifesciences Ltd. (including its subsidiaries/affiliates, hereafter referred to as 'Zydus' today announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.'s (NASDAQ: AGEN) U.S.-based biologics CMC facilities.

  5. Agenus And Zydus Lifesciences Enter $141M Strategic Collaboration To Advance BOT/BAL, Expand Zydus' Biologics Manufacturing In The US 6/3/2025

    Agenus Inc., a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd., including its subsidiaries/affiliates, hereafter referred to as “Zydus,” designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensilimab and balstilimab (BOT/BAL).

  6. TriLink BioTechnologies And Quantoom Biosciences Sign License And Supply Agreement For CleanCap mRNA Capping Technology 6/3/2025

    TriLink BioTechnologies (TriLink), a Maravai LifeSciences company and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics.

  7. Regeneron Expands Clinical-Stage Obesity Portfolio With Strategic In-Licensing Of Novel Dual GLP-1/GIP Receptor Agonist 6/2/2025

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited (“Hansoh”) to acquire exclusive clinical development and commercial rights outside of the Chinese Mainland, Hong Kong and Macau for a dual GLP-1/GIP receptor agonist currently in Phase 3 testing.

  8. STEMCELL Technologies Announces Acquisition Of Cellular Highways 6/2/2025

    STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Cellular Highways Ltd from TTP Group Ltd. Cellular Highways is a biotechnology company based near Cambridge, United Kingdom, that specializes in advanced cell sorting technologies with applications in cell and gene therapy, drug discovery, and general cell research, especially where cells are fragile.

  9. Expansion Of Frontage Laboratories Continues With Launch Of New State-Of-The-Art CRDMO Facility In Exton, PA 6/2/2025

    Frontage Laboratories, Inc. officially unveiled its newest Contract Research, Development and Manufacturing Organization (CRDMO) facility during a grand open house event held on May 22, 2025, at its campus in Exton, Pennsylvania.

  10. Kivu Bioscience Selects Sterling Pharma Solutions For cGMP Manufacturing Of Lead Oncology Antibody-Drug Conjugate KIVU-107 6/2/2025

    Kivu Bioscience, a biotech company developing next-generation antibody-drug conjugates, announced today a manufacturing partnership with Sterling Pharma Solutions, a global contract development and manufacturing organisation, to produce cGMP-quality material for Phase 1 clinical trials of its lead oncology antibody-drug conjugate (ADC) candidate, KIVU-107.